Jeil Pharm (002620) - Total Assets
Based on the latest financial reports, Jeil Pharm (002620) holds total assets worth ₩878.26 Billion KRW (≈ $595.18 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jeil Pharm - Total Assets Trend (2011–2025)
This chart illustrates how Jeil Pharm's total assets have evolved over time, based on quarterly financial data. Also see Jeil Pharm (002620) total market value for the company's overall valuation and market capitalisation.
Jeil Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Jeil Pharm's total assets of ₩878.26 Billion consist of 42.6% current assets and 57.4% non-current assets. Review 002620 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.4% |
| Accounts Receivable | ₩162.03 Billion | 18.5% |
| Inventory | ₩118.84 Billion | 13.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩15.82 Billion | 1.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Jeil Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Jeil Pharm stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jeil Pharm's current assets represent 42.6% of total assets in 2025, a decrease from 67.1% in 2011.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, up from 5.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 18.5% of total assets.
Jeil Pharm Competitors by Total Assets
Key competitors of Jeil Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥10.50 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥2.33 Billion |
Jeil Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.22 | 1.12 | 1.21 |
| Quick Ratio | 0.84 | 0.79 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩68.66 Billion | ₩42.13 Billion | ₩64.27 Billion |
Jeil Pharm - Advanced Valuation Insights
This section examines the relationship between Jeil Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | ₩876.66 Billion |
| Market Capitalization | $79.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jeil Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jeil Pharm's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jeil Pharm (2011–2025)
The table below shows the annual total assets of Jeil Pharm from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩876.66 Billion ≈ $594.10 Million |
-1.55% |
| 2024-12-31 | ₩890.43 Billion ≈ $603.43 Million |
+1.19% |
| 2023-12-31 | ₩880.00 Billion ≈ $596.36 Million |
+1.65% |
| 2022-12-31 | ₩865.68 Billion ≈ $586.66 Million |
-3.00% |
| 2021-12-31 | ₩892.42 Billion ≈ $604.78 Million |
+0.57% |
| 2020-12-31 | ₩887.40 Billion ≈ $601.37 Million |
+4.83% |
| 2019-12-31 | ₩846.47 Billion ≈ $573.64 Million |
-8.00% |
| 2018-12-31 | ₩920.09 Billion ≈ $623.53 Million |
+365.66% |
| 2017-12-31 | ₩197.59 Billion ≈ $133.90 Million |
-59.84% |
| 2016-12-31 | ₩491.98 Billion ≈ $333.41 Million |
+10.52% |
| 2015-12-31 | ₩445.17 Billion ≈ $301.68 Million |
+13.92% |
| 2012-12-31 | ₩390.77 Billion ≈ $264.82 Million |
+1.73% |
| 2011-12-31 | ₩384.13 Billion ≈ $260.32 Million |
-- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more